Although conventional therapy (pharmacologic doses of vitamin D and phosphorus supplementation) is usually successful in healing the rachitic bone lesion in patients with X-linked hypophosphatemic rickets, it does not heal the coexistent osteomalacia. Because serum 1,25-dihydroxyvitamin D levels are inappropriately low in these patients and high calcitriol concentrations may be required to heal the osteomalacia, we chose to treat five affected subjects with high doses of calcitriol (68.2±10.0 ng/kg total body weight/d) and supplemental phosphorus (1-2 g/d) performing metabolic studies and bone biopsies before and after 5-8 mo of this therapy in each individual.
Introduction
X-linked hypophosphatemic rickets/osteomalacia (XLH)' is a disorder characterized by renal phosphate wasting and abnormal mineralization of bone. The defective bone mineralization results in rachitic changes at the growth plate and osteomalacia in trabecular and cortical bone. Traditional therapy with phosphorus supplementation and pharmacologic doses of vitamin D often reverses the roentgenographic signs of active rickets in XLH-affected children without healing their coexistent osteomalacia (1) .
Recent work by several groups suggests that vitamin D metabolism is also deranged in patients with XLH (2, 3, 4) . While hypophosphatemia is a potent stimulus for calcitriol production and increases plasma levels of this metabolite in several mammalian species (5, 6, 7) , patients with XLH maintain a plasma 1,25-dihydroxyvitamin D [1, 25(OH) 2D] concentration only within the normal range. This observation has led investigators to use low doses of this vitamin D metabolite (up to 1 gg/d) in conjunction with phosphorus supplementation, in an attempt to correct the XLH-associated metabolic defect(s) more directly (8, 9) . While roentgenographic cure of the rachitic lesion in XLH is effected with this therapy, bone biopsies show persistent osteomalacia in these patients (1) . The failure of this regimen may be due to the fact that low doses of calcitriol do not elevate plasma 1,25(OH)2D levels into the supraphysiologic range.
In this study we chose to treat affected patients with high doses (>1 gg/d or >55 ng/kg ideal body weight [IBW] per day) of 1,25(OH)2D3 (in conjunction with phosphorus supplementation) in an effort to more closely simulate the normal response to low serum phosphorus. We evaluated the therapeutic response by comparing metabolic and bone biopsy data in five patients before and after high dose calcitriol therapy. We continued to follow four of these patients for a mean of nearly 2 yr after the second bone biopsy. During this followup period all subjects required calcitriol dose reductions because of persistent hypercalciuria or hypercalcemia. Metabolic and bone biopsy data were obtained on each patient after 11.4±0.9 mo of reduced dose therapy.
Methods
Patient population. We studied five patients with hypophosphatemia and osteomalacia from four families in which an inheritance pattern compatible with X-linked dominant transmission was demonstrated. Two females (one, aged 2 yr, 2 mo; and the other, 37 yr) were untreated on entry into the study. Two males and a female (aged 13 yr, 8 mo; 19 yr, 8 mo; and 13 yr, 10 mo, respectively) had been treated with vitamin D (20,000-75,000 IU/d) and phosphorus (2 g/d) for more than 6 mo. Of the previously untreated patients, the 2 yr, 2 mo-old child had roentgenographic signs of active rickets at inception of the study, while the 37-yr-old woman exhibited a femoral pseudofracture and short stature. All patients previously treated with conventional therapy had characteristic postrachitic deformities, but no evidence of active rickets.
High dose calcitriol and phosphorus regimen. After an average vitamin D free interval of 4 wk in previously treated patients, all subjects received calcitriol for a mean of 10 mo (range, 8-11 mo) . Over the first 3-4 mo of therapy, doses were titrated to a peak that was maintained for an average of 6.4±0.6 mo (range, 5-8 mo Experimental. We performed metabolic studies and bone biopsies in each subject before and after high dose calcitriol and phosphorus therapy. Subsequently, we completed similar studies in four of the five subjects after they were switched to and maintained on low dose calcitriol and phosphorus therapy. The base-line (precalcitriol) studies in subjects previously treated with vitamin D and phosphorus were conducted while they were taking these medications. The patient or the patient and his/her parents gave informed consent for all studies. These investigations were approved by the Duke University Human Investigations Committee and were performed on the Duke University Clinical Research Unit.
Biochemical studies. Serum calcium (normal, 8.7-10.2 mg/dl) was measured by atomic absorption spectrophotometry and serum phosphorus (for age specific normals, see Table I ) was determined by the colorimetric method of Dryer et al. (10) . Serum creatinine (normal, 0.7-1.2 mg/dl) and alkaline phosphatase (for age specific normals, see Table I ) were determined on the Multichannel Technicon Autoanalyzer (Technicon Instruments Corp., Tarrytown, NY). Urine specimens were stored at -20'C before analysis of calcium (by atomic absorption spectrophotometry), phosphorus (1 1), and creatinine (12) .
The renal tubular maximum for the reabsorption of phosphorous (Pi) normalized according to the glomerular filtration rate was calculated by the method of Bijvoet and Walton (13) . Studies were performed as previously described (14) and age specific normals are shown in Table  I Histomorphometric analysis of the trabecular bone in the section was accomplished by examining 25-50 microscopic fields with a Merz integrated reticle (23). The following histological functions were quantitated: (a) mineralization front activity, the percentage of osteoidcovered trabecular bone surface (OS) exhibiting a fluorescent chlortetracycline second (distinguished by color from the first label-declomycin) label with a minimum width of 3 Am; (b) mineral apposition rate, the average distance (in micrometers) between declomycin and chlortetracycline fluorescent labels normalized by the days elapsed between the administration of the labels; (c) mean osteoid seam width, the mean width (in micrometers), of 25-50 randomly selected osteoid seams, each measured at four points equidistant from each other using a linear reticle calibrated with a stage micrometer, (d) osteoid surface, the percentage of trabecular bone surface covered by osteoid; (e) active resorption surface, the percentage of trabecular bone surface on which Howship's lacunae containing multinucleated osteoclasts are present; (f) osteoblastic surface, the percentage of trabecular bone surface on which osteoid covered by osteoblasts is present; (g) relative osteoid volume, the percentage of trabecular bone volume composed of unmineralized bone; and (h) bone volume, the percentage of the sample composed of trabecular bone. In addition, mineralization lag time, a measure of the time (in days) that newly formed osteoid remains unmineralized, was calculated by dividing the mean osteoid seam width by the corrected mineral apposition rate (24) . Normal values for these measurements (apart from mineralization dynamics) were determined in bone biopsies from 12 normal subjects, aged 5-35 yr. Normal values for mineralization dynamic measurements were obtained from the bone biopsies of six normal subjects kindly provided by Dr. Michael Parfitt (Detroit, MI) and from normal ranges in the medical literature (25, 26) .
Statistical analyses. Statistical evaluation ofthe data was performed using analysis of variance with Tukey's studentized range testing (27).
Materials. Table III ). In untreated patients mineralization dynnics assessed by measurement of mineralization front activity (MFA) and mineral apposition rate (MiAR) were characteristically abnormal ( Fig. 1 C, and Table  III ). In contrast, although MFA was quantitatively normalized by conventional therapy in patients 3-5, the incorporated label appeared qualitatively abnormal, as evidenced by smudged, nondiscrete chlortetracycline bands (Fig. 1 D) . In any case, the continued presence of a subnormal MiAR confirmed the persistence of a disturbance in bone mineralization (Table III) (Table I) . Similarly, serum calcium concentrations increased in each patient, resulting in a small but significant difference between average pre-treatment and post-treatment levels. Despite this increment, no significant change in serum PTH occurred with calcitriol therapy (Table II) . Glomerular filtration rates, as reflected by creatinine clearance determinations, rose significantly upon calcitriol administration; in the instance of the 2 yr, 2 mo-old child (patient 1), the increase was in accord with normal expectations (28).
Bone histomorphometry on high dose calcitriol therapy. High doses of calcitriol and phosphorus therapy resulted in changes of both static and dynamic bone histomorphometric parameters indicative of bone healing (Table III, Fig. 2 (Fig. 2 C) . In addition, the mean osteoid seam width (MOSW) was normalized in all patients (1 1.0±1.0 ,Am, (Table I) . Bone histomorphometry on reduced dose calcitriol therapy. All four bone biopsies procured from previously healed patients on reduced doses of 1,25(OH)2D3 were qualitatively normal ( Fig. 2 B and D) . Static histomorphometric parameters confirmed the subjective impression of normality obtained from histologic inspection. MOSW and ROV remained normal in each patient (13.5±0.8 ,um and 1.5±0.4%, respectively), while the previously demonstrated persistent elevation of OS in patient 5 disappeared. Indices of bone cellular activity (AR and ObS) were diminished by the lowered plasma calcitriol levels in these patients (Table III) (30) . With the recognition that the manifestations of XLH might be due to Pi depletion, phosphorus supplementation was added to this traditional therapeutic regimen in an attempt to raise the serum Pi concentration (31, 32) . Pharmacologic amounts of vitamin D were employed to prevent the secondary hyperparathyroidism that may be induced by administration of Pi. While this combination therapy results in roentgenographic healing of the physeal rachitic lesions in affected subjects, the mineralization of endosteal and cortical bone surfaces remains abnormal (33) .
Recently, the recognition that a defect in the homeostatic regulation of 1,25(OH)2D3 biosynthesis may contribute to the pathogenesis of XLH has prompted therapeutic trials of calcitriol or la-hydroxyvitamin D3 in conjunction with Pi supplements (1, (34) (35) (36) Moreover, with the achievement of elevated calcitriol levels, all of the treated patients manifested normal bone mineralization dynamics (Table III) . At the inception of the study, conventionally treated patients (numbers 3-5) had some smudged and nondiscrete fluorescent labeling of bone (Fig. 1   D) while untreated patients (numbers 1 and 2) had little or no label incorporation (Fig. 1 C, Table III ). In contrast, after treatment with high dose calcitriol/phosphorus, all subjects manifested a normal MFA, MiAR, and MLT. In addition, ROV and OS improved to values well within the normal range. Nevertheless, patients 1 and 5 continued to exhibit abnormal amounts of osteoid on the bone surface and/or increased ROV at the second biopsy. A subsequent biopsy in patient 5 (23 mo later), which showed a normal ROV and OS, suggests that these apparent defects were the consequence of a relatively short duration of full dose calcitriol therapy (5 mo in patients 1 and 5) rather than indicative of insurmountable calcitriol/phosphorus resistance.
In addition to evidence of healing, the bone biopsies obtained during high dose calcitriol treatment showed an apparent increase in bone resorption and formation surfaces to levels that remained within the normal range (Table III) . While it is possible that the increased osteoclastic and osteoblastic activity is due to MiAR, 0.88±0.10 Am/d), the serum Pi concentration fell to the precalcitriol treatment level (2.50±0.11 mg/dl) in conjunction with a TmP/GFR decrement to 1.74±0.05 mg/dl. Thus, bone healing was maintained for nearly a year in the setting of recrudescent hyperphosphaturia and hypophosphatemia.
The use of supplemental Pi in patients with XLH has been associated with an increased incidence of secondary hyperparathyroidism (32). Using two PTH assays that recognize COOH-terminal and intact molecule determinants, we found no significant change of the circulating PTH level in the pretreatment and post-treatment periods (Table II) . A third assay with midmolecule specificity showed a progressive increase of parathyroid hormone levels across the three periods, but all values remained within the normal range. Thus, the concurrent administration of 1,25(OH)2D3 effectively prevented PTH hypersecretion often seen in patients given supplemental Pi. Other potential side effects of calcitriol/Pi therapy include hypercalcemia, hypercalciuria, and renal dysfunction (38) . During the induction of bone healing, we did not encounter any of these complications. Indeed, creatinine clearance determinations actually rose during high dose calcitriol therapy in three of five patients. However, within 1-17 mo of bone healing (as documented by the second bone biopsy), all four patients remaining in the study developed hypercalciuria or hypercalcemia, which necessitated calcitriol dose reductions. Subsequently, although the serum calcium concentration and urinary calcium excretion decreased remarkably, creatinine clearances, which had fallen to a nadir of 66±4 ml/min during the complication period, remained depressed at 86±7 ml/min (Table I) (42, 43) . These studies show that D metabolites can alter phosphate transport in isolated renal tubules. Similar effects of 1,25(OH)2D3 on the sodium-dependent phosphate transport of isolated chick renal cells and of rat brush border membranes have been reported (44, 45) . The fact that TmP/GFR remains subnormal (although improved from pre-treatment values) in humans with XLH who are treated with pharmacologic doses of 1,25(OH)2D3 alone, however, does not substantiate this hypothesis (19). In addition, the failure of low dose 1 ,25(OH)2D3 and Pi regimens to effect a similar directional change of TmP/ GFR to that which we observed is unexplained (1, 36, 46) . However, methodologic differences may account for this disparity. Glorieux and associates (1, 36) collected blood and urine for estimation of TmP/GFR on a morning when all medicines were withheld. Thus, the beneficial effects of supraphysiologic calcitriol levels or Pi on renal phosphorus handling may have been overlooked. In contrast, we administered medication -1 h before initiation of the first 2-h urine collection and 2 h before the first blood collection. Administering the drug allowed us to determine with greater certainty whether the treatment regimen affected the TmP/GFR. Alon and Chan (47) have reported beneficial effects of calcitriol/Pi therapy on renal phosphorus threshold using similar methods. Therefore, it is possible that high doses of 1,25(OH)2D3 and Pi favorably affect renal phosphorus handling when measured under appropriate circumstances.
In conclusion, our data support the view that combined Pi and high-dose calcitriol (55-70 ng/kg IBW per day) therapy is the initial treatment of choice in patients with XLH. Such therapy results in complete healing of the bone disease and amelioration of the characteristic abnormal biochemistries. On this regimen, hypercalcemia or hypercalciuria inevitably occur, necessitating careful follow-up and eventual calcitriol dose reduction. Early detection of these complications is essential since reduced renal glomerular function may quickly ensue and persist after dose reduction. Although reduced doses of 1,25(OH)2D3 do not maintain normophosphatemia in these patients, bone healing is persistent for at least 11 mo. Further studies are necessary to determine whether shorter courses of high dose therapy can promote bone healing while avoiding complications, and to resolve whether treatment with low doses of calcitriol can maintain normal bone mineralization for even longer periods of time.
